BD reports positive 9-month results for iliac artery stent trial
BD (BDX) reported nine-month results from the iliac cohort of the AGILITY trial for its Revello Vascular Covered Stent, meeting primary endpoints with a 2.8% failure rate. The study showed 97.2% primary patency and 98.3% freedom from revascularization, with no device-related deaths. The stent is CE marked but investigational in the U.S. BD completed enrollment in the study’s superficial femoral and proximal popliteal artery cohort in August.
How this was made
The 30-second read
Why it matters
The trial met its primary endpoint with a failure rate far below the target, suggesting strong commercial potential.
Market read
First disclosure of pivotal trial data for a major medtech firm; likely to influence BD's near‑term stock movement.
What to watch
Regulatory approval timeline in the U.S. remains uncertain; reimbursement decisions could temper upside.
Background
BD (NYSE:BDX) released first‑time nine‑month results from the AGILITY investigational device exemption trial for its Revello Vascular Covered Stent.
Ticker impact
BD announced nine‑month results of the iliac cohort of the AGILITY trial, showing a 2.8% failure rate versus a 19% goal and 97.2% primary patency.
likely upward pressure as investors price in the favorable clinical outcomes
First disclosure of pivotal trial results for a marketed device; large‑cap medtech company; data exceeds performance benchmarks.
Market effects
Positive data could boost confidence in vascular device segment and spur competitor activity.
U.S. and European medtech markets may see modest gains.
Limited to medtech investors; no broad market effect.
Counterpoint
If longer‑term data reveal safety issues, the initial rally could reverse.
Key entities
- companyBD
Medical device maker reporting trial results.
- productRevello Vascular Covered Stent
Device evaluated in the AGILITY trial.
